Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2016 (2016), Article ID 1507270, 7 pages
http://dx.doi.org/10.1155/2016/1507270
Research Article

A Genetic Biomarker of Oxidative Stress, the Paraoxonase-1 Q192R Gene Variant, Associates with Cardiomyopathy in CKD: A Longitudinal Study

1Department of Nephrology, University Hospital of Ioannina, 45110 Ioannina, Greece
2Laboratory of Clinical Genetics and Human Reproduction, Medical School University of Ioannina, 45110 Ioannina, Greece
3CNR-IFC, Clinical Epidemiology and Physiopathology of Renal Diseases and Hypertension, 89124 Reggio Calabria, Italy
4Department of Cardiology, University Hospital of Ioannina, 45110 Ioannina, Greece
5Laboratory of Biochemistry, Department of Chemistry, University of Ioannina, 45110 Ioannina, Greece
6Department of Internal Medicine, University Hospital of Ioannina, 45110 Ioannina, Greece
7Department of Nephrology, General Hospital “Papageorgiou” of Thessaloniki, 564 29 Thessaloniki, Greece

Received 11 March 2016; Revised 24 April 2016; Accepted 5 May 2016

Academic Editor: José Pedraza-Chaverri

Copyright © 2016 E. Dounousi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. B. Devereux, P. M. Okin, and M. J. Roman, “Left ventricular hypertrophy as a surrogate end-point in hypertension,” Clinical and Experimental Hypertension, vol. 21, no. 5-6, pp. 583–593, 1999. View at Publisher · View at Google Scholar · View at Scopus
  2. G. B. J. Mancini, B. Dahlöf, J. Díez, and J. N. Cohn, “Surrogate markers for cardiovascular disease: structural markers,” Circulation, vol. 109, no. 25, pp. IV-22–IV-30, 2004. View at Google Scholar · View at Scopus
  3. T. J. Wang, J. C. Evans, E. J. Benjamin, D. Levy, E. C. LeRoy, and R. S. Vasan, “Natural history of asymptomatic left ventricular systolic dysfunction in the community,” Circulation, vol. 108, no. 8, pp. 977–982, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. T. B. Drüeke, F. Locatelli, N. Clyne et al., “Normalization of hemoglobin level in patients with chronic kidney disease and anemia,” The New England Journal of Medicine, vol. 355, no. 20, pp. 2071–2084, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. G. M. Chertow, N. W. Levin, G. J. Beck et al., “In-center hemodialysis six times per week versus three times per week,” The New England Journal of Medicine, vol. 363, no. 24, pp. 2287–2300, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Cice, L. Ferrara, A. Di Benedetto et al., “Dilated cardiomyopathy in dialysis patients—beneficial effects of carvedilol: a double-blind, placebo-controlled trial,” Journal of the American College of Cardiology, vol. 37, no. 2, pp. 407–411, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Park, C.-Y. Hsu, Y. Li et al., “Associations between kidney function and subclinical cardiac abnormalities in CKD,” Journal of the American Society of Nephrology, vol. 23, no. 10, pp. 1725–1734, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. N. Bansal, M. Keane, P. Delafontaine et al., “A longitudinal study of left ventricular function and structure from CKD to ESRD: the CRIC study,” Clinical Journal of the American Society of Nephrology, vol. 8, no. 3, pp. 355–362, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. R. N. Foley, P. S. Parfrey, J. D. Harnett, G. M. Kent, D. C. Murray, and P. E. Barre, “The prognostic importance of left ventricular geometry in uremic cardiomyopathy,” Journal of the American Society of Nephrology, vol. 5, no. 12, pp. 2024–2031, 1995. View at Google Scholar · View at Scopus
  10. C. Zoccali, F. A. Benedetto, F. Mallamaci et al., “Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis,” Journal of the American Society of Nephrology, vol. 12, no. 12, pp. 2768–2774, 2001. View at Google Scholar · View at Scopus
  11. C. Zoccali, D. Bolignano, and F. Mallamaci, “Left ventricular hypertrophy in chronic kidney disease,” in Oxford Textbook of Nephrology, N. Turner, D. Goldsmith, C. Winearls, N. Lameire, J. Himmelfarb, and G. Remuzzi, Eds., Oxford University Press, Oxford, UK, 2015. View at Google Scholar
  12. M. Mizobuchi, H. Nakamura, M. Tokumoto et al., “Myocardial effects of VDR activators in renal failure,” Journal of Steroid Biochemistry and Molecular Biology, vol. 121, no. 1-2, pp. 188–192, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. K. Yang, C. Wang, L. Nie et al., “Klotho protects against indoxyl sulphate-induced myocardial hypertrophy,” Journal of the American Society of Nephrology, vol. 26, no. 10, pp. 2434–2446, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. E. Takimoto and D. A. Kass, “Role of oxidative stress in cardiac hypertrophy and remodeling,” Hypertension, vol. 49, no. 2, pp. 241–248, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. S. P. Deakin and R. W. James, “Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1,” Clinical Science, vol. 107, no. 5, pp. 435–447, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. K. Kowalska, E. Socha, and H. Milnerowicz, “Review: the role of paraoxonase in cardiovascular diseases,” Annals of Clinical and Laboratory Science, vol. 45, no. 2, pp. 226–233, 2015. View at Google Scholar · View at Scopus
  17. S. Billecke, D. Draganov, R. Counsell et al., “Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters,” Drug Metabolism and Disposition, vol. 28, no. 11, pp. 1335–1342, 2000. View at Google Scholar · View at Scopus
  18. M. Aviram, M. Rosenblat, C. L. Bisgaier, R. S. Newton, S. L. Primo-Parmo, and B. N. La Du, “Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions: a possible peroxidative role for paraoxonase,” The Journal of Clinical Investigation, vol. 101, no. 8, pp. 1581–1590, 1998. View at Publisher · View at Google Scholar · View at Scopus
  19. J. G. Wheeler, B. D. Keavney, H. Watkins, R. Collins, and J. Danesh, “Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies,” The Lancet, vol. 363, no. 9410, pp. 689–695, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. D. A. Lawlor, I. N. M. Day, T. R. Gaunt et al., “The association of the PON1 Q192R polymorphism with coronary heart disease: findings from the British Women's Heart and Health cohort study and a meta-analysis,” BMC Genetics, vol. 5, article 17, 2004. View at Google Scholar · View at Scopus
  21. N. Pérez-Herrera, C. May-Pech, I. Hernández-Ochoa et al., “PON1Q192R polymorphism is associated with lipid profile in Mexican men with Mayan ascendancy,” Experimental and Molecular Pathology, vol. 85, no. 2, pp. 129–134, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Vaisi-Raygani, H. Ghaneialvar, Z. Rahimi et al., “Paraoxonase Arg 192 allele is an independent risk factor for three-vessel stenosis of coronary artery disease,” Molecular Biology Reports, vol. 38, no. 8, pp. 5421–5428, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Ichikawa, T. Konta, M. Emi et al., “Genetic polymorphisms of paraoxonase-1 are associated with chronic kidney disease in Japanese women,” Kidney International, vol. 76, no. 2, pp. 183–189, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. T. Suehiro, Y. Ikeda, T. Shiinoki et al., “Serum paraoxonase (PON1) concentration in patients undergoing hemodialysis,” Journal of Atherosclerosis and Thrombosis, vol. 9, no. 3, pp. 133–138, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. W. H. Wilson Tang, Y. Wu, S. Mann et al., “Diminished antioxidant activity of high-density lipoprotein-associated proteins in systolic heart failure,” Circulation: Heart Failure, vol. 4, no. 1, pp. 59–64, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. G. D. Smith and G. Hemani, “Mendelian randomization: genetic anchorsfor causal inference in epidemiological studies,” Human Molecular Genetics, vol. 23, no. 1, Article ID ddu328, pp. R89–R98, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. V. S. Stel, K. Ioannou, K. Brück et al., “Longitudinal association of body mass index and waist circumference with left ventricular mass in hypertensive predialysis chronic kidney disease patients,” Nephrology Dialysis Transplantation, vol. 28, supplement 4, pp. iv136–iv145, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. M. A. Quinones, A. D. Waggoner, L. A. Reduto et al., “A new simplified and accurate method for determining ejection fraction with two-dimensional echocardiography,” Circulation, vol. 64, no. 4, pp. 744–753, 1981. View at Publisher · View at Google Scholar · View at Scopus
  29. P. S. Tucker, V. J. Dalbo, T. Han, and M. I. Kingsley, “Clinical and research markers of oxidative stress in chronic kidney disease,” Biomarkers, vol. 18, no. 2, pp. 103–115, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. M. M. Suttorp, B. Siegerink, K. J. Jager, C. Zoccali, and F. W. Dekker, “Graphical presentation of confounding in directed acyclic graphs,” Nephrology Dialysis Transplantation, vol. 30, no. 9, pp. 1418–1423, 2015. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Sabri, H. H. Hughie, and P. A. Lucchesi, “Regulation of hypertrophic and apoptotic signaling pathways by reactive oxygen species in cardiac myocytes,” Antioxidants and Redox Signaling, vol. 5, no. 6, pp. 731–740, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. E. Takimoto, H. C. Champion, M. Li et al., “Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load,” The Journal of Clinical Investigation, vol. 115, no. 5, pp. 1221–1231, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. J. Himmelfarb, P. Stenvinkel, T. A. Ikizler, and R. M. Hakim, “Perspectives in renal medicine: the elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia,” Kidney International, vol. 62, no. 5, pp. 1524–1538, 2002. View at Publisher · View at Google Scholar · View at Scopus
  34. F. Locatelli, B. Canaud, K.-U. Eckardt, P. Stenvinkel, C. Wanner, and C. Zoccali, “Oxidative stress in end-stage renal disease: an emerging treat to patient outcome,” Nephrology Dialysis Transplantation, vol. 18, no. 7, pp. 1272–1280, 2003. View at Publisher · View at Google Scholar · View at Scopus
  35. N. Gupta, S. Singh, V. N. Maturu, Y. P. Sharma, and K. D. Gill, “Paraoxonase 1 (PON1) polymorphisms, haplotypes and activity in predicting CAD risk in North-West Indian Punjabis,” PLoS ONE, vol. 6, no. 5, Article ID e17805, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. D. J. Kennedy, W. H. W. Tang, Y. Fan et al., “Diminished antioxidant activity of high-density lipoprotein-associated proteins in chronic kidney disease,” Journal of the American Heart Association, vol. 2, no. 2, Article ID e000104, 2013. View at Publisher · View at Google Scholar · View at Scopus